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Abstract
Introduction It was recently suggested that heat shock protein
(HSP)70, an intracellular protein, is a potential mediator of
inflammatory disease when it is released into the extracellular
compartment. Although elevated HSP70 levels have been
identified in rheumatoid arthritis (RA) synovial tissues and RA
synovial fluid compared with patients with osteoarthritis and
healthy individuals, it remains unclear what role extracellular
HSP70 plays in the pathogenesis of RA. This study was
conducted to investigate the effects of extracellular HSP70 on
the production of RA-associated cytokines in fibroblast-like
synoviocytes from patients with RA and to elucidate the
mechanisms involved.
Methods IL-6, IL-8 and monocyte chemoattractant protein
(MCP)-1 levels in culture supernatants were measured using
enzyme-linked immunosorbent assays. Activation of mitogen-
activated protein kinases (MAPKs), such as extracellular signal-
regulated protein kinases (ERKs), c-Jun amino-terminal kinase
(JNK) and p38 MAPK, was detected using Western blotting.
Nuclear translocation of nuclear factor-κB (NF-κB) and
degradation of the inhibitory protein IκBα were examined using
immunohistochemistry and Western blotting.
Results Human HSP70 downregulated IL-6, IL-8 and MCP-1
production in RA fibroblast-like synoviocytes induced by tumour
necrosis factor (TNF)-α in a concentration dependent manner.
HSP70 inhibited the activation of ERK, JNK and p38 MAPK in
fibroblast-like synoviocytes stimulated by TNF-α. Furthermore,
HSP70 also significantly inhibited nuclear translocation of
nuclear factor-κB and degradation of IκBα induced by TNF-α.
Conclusion Extracellular HSP70 has an anti-inflammatory effect
on RA by downregulating production of IL-6, IL-8 and MCP-1 in
fibroblast-like synoviocytes, which is mediated through inhibited
activation of the MAPKs and NF-κB signal pathways.
Introduction
Rheumatoid arthritis (RA) is a chronic disease that is charac-
terized by inflammation of the synovial membrane and prolifer-
ation of the synovial lining, resulting in progressive joint
destruction [1]. Fibroblast-like synoviocytes (FLSs) play a cru-
cial role in the joint inflammation and destructive process [2].
RA FLSs respond to several proinflammatory cytokines,
including IL-1, tumour necrosis factor (TNF)-α, and exhibit
characteristics of inflammatory cells that are critically involved
in various aspects of rheumatoid pathophysiology [2,3]. They
synthesize and secrete proinflammatory cytokines such as IL-
6, and chemokines including IL-8 and monocyte
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chemoattractant protein (MCP)-1 [4-7], which play roles in
mediating the inflammatory functions of FLSs. IL-6 is now rec-
ognized to be a master cytokine that is involved not only in the
RA cytokine cascade but also in actions such as promotion of
expansion and activation of T cells, differentiation of B cells,
regulation of acute phase protein genes, and regulation of
chemokine production [8,9]. IL-8 and MCP-1 are key media-
tors that are involved in the recruitment of neutrophils, mono-
cytes and lymphocytes, and play important roles in
inflammatory cell infiltration [8]. Evidence from animal models
of arthritis and from RA patients has shown that blockade of
these cytokines or their receptors has beneficial effects both
for inflammation and joint destruction [10-12]. Therefore, inhi-
bition of these inflammatory mediators production by FLSs
might present an effective target for RA treatment.
Heat shock proteins (HSPs) are a family of highly conserved
intracellular proteins that are found in all prokaryotes and
eukaryotic cells. Although some HSPs are constitutively
expressed, upregulation of expression is caused by exposure
to a variety of cellular stressors, including heat shock, growth
factors, inflammation and infection [13,14]. HSPs are typically
regarded as intracellular proteins, and their primary function
appears to be that of intracellular molecular chaperones, con-
tributing to the folding of nascent proteins and denatured pro-
teins, and thus preventing protein aggregation under stressful
stimuli [15,16]. The human stress-inducible form of the 70 kDa
HSP (HSP70; Genbank: NM005345) is a many-faceted mol-
ecule. In addition to serving as a intracellular chaperone, it is
released from damaged cells or viable cells after stress, and
has been found in the bloodstream of both healthy individuals
and those suffering from autoimmune diseases and inflamma-
tory conditions [17,18]. Recent findings indicating a role for
extracellular HSP70 as a cytokine that induces secondary
proinflammatory cytokine (TNF-α, IL-1 and IL-6) production
may provide insight into the pathogenesis of autoimmune dis-
ease [16,19].
Elevated levels of the inducible form of HSP70 have been
identified in RA synovial tissues and RA synovial fluid relative
to those in patients with osteoarthritis and healthy individuals
[20,21]. It is unknown whether an increase in extracellular
HSP70 plays a biological role in RA, but in animal models pre-
immunization with proteins of the HSP70 family, such as
mycobacterial HSP70 and the glucose-regulated protein 78,
protected animals from experimentally induced arthritis. In
adjuvant-induced arthritis in rats it was shown that the protec-
tion conferred by mycobacterial HSP70 resulted from the
induction of IL-10 producing T cells that were capable of
downregulating inflammation [22-24]. However, the precise
mechanism of protection by HSP70 in RA remains unclear.
Findings in arthritis models raise the question of whether
HSP70 could play a role in FLSs. Analyses of FLSs from
human patients with RA reveal significantly elevated extracel-
lular expression of HSP70 [25], which suggests that extracel-
lular HSP70 may play an immunomodulatory role in FLSs.
However, the interactions of HSP70 with FLSs in RA have not
previously been reported. Also unknown are whether HSP70
exogenously regulates production by FLSs of RA-associated
proinflammatory mediators.
In the present study we report the first analysis of the effects
of extracellular human inducible HSP70 on TNF-α induced
secretion by RA FLSs of the proinflammatory cytokine IL-6 and
the chemokines IL-8 and MCP-1, and we elucidate the under-
lying mechanism. We find that human HSP70 inhibits TNF-α
induced IL-6, IL-8 and MCP-1 secretion by human RA FLSs.
Furthermore, we demonstrate that human HSP70 suppresses
the activation of nuclear factor-κB (NF-κB) and mitogen-acti-
vated protein kinase (MAPK) signalling pathways induced by
TNF-α. These findings clearly reveal an anti-inflammatory
effect of human HSP70 on TNF-α-mediated inflammation and
demonstrate its mechanism in RA FLSs.
Materials and methods
Cell culture
FLSs were isolated from RA synovial tissues obtained at joint
replacement surgery, as previously described [26]. The diag-
noses of RA conformed to the 1987 revised American Council
of Rheumatology criteria [27]. Briefly, tissue samples were
minced and treated with 1 mg/ml collagenase for 1 to 2 hours
at 37°C. After washing, the cells were cultured in Dulbecco's
modified Eagle's medium (Life Technologies, Rockville, MD,
USA) supplemented with 10% heat-inactivated foetal calf
seum (Life Technologies), 100 IU/ml penicillin, 100 μg/ml
streptomycin, and 2 mmol/l L-glutamine in a humidified incuba-
tor with 5% carbon dixoide and 95% air. After overnight cul-
ture nonadherent cells were removed, and adherent cells were
cultivated in Dulbecco's modified Eagle's medium plus 10%
foetal calf seum. At confluence, cells were trypsinized, split at
a 1:3 ratio and re-cultured in the same medium. All the experi-
ments described here utilize FLSs between the fourth and
ninth passage. That the population of FLSs was homogeneous
was determined using flow cytometry (<1% CD11b, <1%
phagocytic and <1% Fcγ receptor type II positive).
Cytokine quantification by ELISA
Following stimulation of human RA FLSs by TNF-α (R&D, Min-
neapolis, MN, USA) in the presence or absence of recom-
binant human inducible HSP70 (StressGen, Victoria, British
Columbia, Canada; catalog# ESP555), supernatants were
harvested. IL-6, IL-8 and MCP-1 levels were measured using a
sandwich ELISA, following the manufacturer's instructions
(R&D). All data were normalized by cell number.
Preparation of cellular extracts
Following treatment with TNF-α, cells were harvested, washed
twice with cold phosphate-buffered saline (PBS), and nuclear
and cytoplasm extracts were prepared in accordance with the
method proposed by Edgar and coworkers [28]. Briefly, theAvailable online http://arthritis-research.com/content/10/2/R41
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cell pellet was resuspended in 200 μl cold buffer A (10 mmol/
l HEPES [pH 7.9], 10 mmol/l KCl, 0.1 mmol/l EDTA, 0.1 mmol/
l EGTA, 1 mmol/l DTT and 0.5 mmol/l phenylmethylsulphonyl
fluoride [PMSF]). The cells were allowed to swell on ice for 15
minutes, after which 25 μl of a 10% solution of NP-40 was
added and the tube was vortexed for 10 seconds. The
homogenate was centrifuged for 30 seconds in a microfuge to
recover the cytoplasm extract in the supernatant. The nuclear
pellet was resuspended in 50 μl ice-cold buffer B (20 mmol/l
HEPES [pH 7.9], 0.4 mol/l NaCl, 1 mmol/l EDTA, 1 mmol/l
EGTA, 1 mmol/l DTT and 1 mmol/l PMSF) and the tube was
vigorously rocked at 4°C for 15 minutes on a shaking platform.
The nuclear homogenate was centrifuged for 5 minutes to
recover the nuclear extract in the supernatant. The aliquots
were stored at -80°C. The protein concentrations of the frac-
tions were determined using a standard Bradford assay.
Western blot analysis
The following antibodies were used in this study: rabbit anti-
phospho-JNK (c-Jun amino-terminal kinase) polyclonal anti-
body (Cell Signaling, Danvers, MA, USA; 1:1000); rabbit anti-
phospho-p38 polyclonal antibody (Cell Signaling; 1:1000);
sheep anti-phospho-Erk1/2 (extracellular signal-regulated pro-
tein kinase-1/2) polyclonal antibody (Upstate, Lake Placid, NY,
USA; 1:1000); rabbit anti-NF-κB (nuclear factor-κB) p65 pol-
yclonal antibody (Santa Cruz, Santa Cruz, CA; 1:200); rabbit
anti-JNK polyclonal antibody (Cell Signaling; 1:1000); rabbit
anti-p38 polyclonal antibody (Cell Signaling; 1:1000); rabbit
anti-Erk1/2 polyclonal antibody (Cell Signaling; 1:1000); rab-
bit anti-IκBα polyclonal antibody (Santa Cruz; 1:1000); mouse
anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase)
monoclonal antibody (Upstate; 1:1000); and mouse anti-
PCNA (proliferating cellular nuclear antigen) monoclonal anti-
body (Upstate; 1:1000), and mouse anti-tublin monoclonal
antibody (Upstate; 1:1000).
Aliquots of either subcellular fractions or total cell lysates were
reduced and denatured by boiling in SDS sample buffer (2× =
100 mmol/l Tris-HCl [pH 6.8]; 4% weight/vol SDS; 20% glyc-
erol; 200 mmol/l DTT; 0.1% weight/vol bromophenol blue),
fractionated on 12% SDS-PAGE, and transferred to a nitrocel-
lulose membrane (Promega, Madison, WI, USA). Membranes
were blocked in blocking buffer (2% bovine serum albumin
[BSA], 0.2% Tween-20 in Tris-buffered saline) at room tem-
perature for 4 hours, and incubated for 2 hours at 25°C with
the indicated primary antibody, followed by peroxidase-conju-
gated secondary antibody IgG (anti-rabbit or anti-mouse
[Boster Biotech, Wuhan, China; 1:1000], anti-sheep [KPL,
Gaithersburg, MD, USA; 1:1000]) for 1 hours at 25°C. The
signals were visualized by DAB detection (Boster Biotech),
following the manufacturer's instruction, and the bands of
interest were scanned and counts quantitated with the Band
Leader software (Shanghai, China).
Immunocytochemical analysis
FLSs (5 × 105 cells), cultured on glass coverslips, were fixed
in 4% formaldehyde for 30 minutes at room temperature
before detergent extraction with 0.1% Triton X-100 for 10 min-
utes at 4°C. Coverslips were blocked in PBS containing 2%
BSA for 1 hour at room temperature and processed for
immunofluorescence with rabbit anti-NF-κB/p65 polyclonal
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA; 1:50) followed by Cy3-conjugated sheep anti-rabbit IgG
(Santa Cruz; 1:100) and Hoechst 33258 (Sigma, St. Louis,
MO, USA; 1 μg/ml). Between all incubation steps, cells were
washed three times for 30 minutes with PBS containing 0.2%
BSA. Coverslips were mounted on slides using Movio
(Sigma). Fluorescence signals were analyzed by fluorescent
microscopy (Nikon, Tokyo, Japan).
Statistical analysis
Data in the figures and text were expressed as means ± stand-
ard deviation. P < 0.05 was deemed to represent statistical
significance, and the significance of differences between
groups was determined using two-tailed Student's t-test or
Fisher's least significant difference test.
Results
Human HSP70 inhibits TNF-α induced IL-6, IL-8 and 
MCP-1 secretion in FLSs
It has been demonstrated that IL-6, IL-8 and MCP-1 are key
proinflammatory mediators, produced mainly by FLSs in the
synovium, and play crucial roles in the pathophysiology of RA
[29]. TNF-α is a potent activator of production of these proin-
flammatory mediators in FLSs [8,30]. We therefore analyzed
the effects of human HSP70 on TNF-α induced secretion of
IL-6, IL-8 and MCP-1 in RA FLSs. As demonstrated in Figure
1, TNF-α stimulation (5 to 40 ng/ml) for 24 hours induced a
dose-dependent increase in IL-6, IL-8 and MCP-1 secretion by
the RA FLSs. Peak levels of IL-6, IL-8 and MCP-1 production
were noted with 20 to 40 ng/ml TNF-α. In contrast to TNF-α,
human HSP70 (0.1 to 10 μg/ml) alone had no significant
effects on secretion by RA FLSs of IL-6, IL-8 and MCP-1 (Fig-
ure 1). However, when the FLSs were pretreated with different
concentrations of human HSP70 for 1 hour, washed and then
exposed to TNF-α (20 ng/ml) for 24 hours, secretion of IL-6,
IL-8 and MCP-1 was inhibited. As shown in Figure 2, levels of
production of IL-6, IL-8 and MCP-1 were increased after TNF-
α stimulation as compared with untreated controls, and the
TNF-α induced increases in IL-6, IL-8 and MCP-1 secretion
were attenuated in cells treated with HSP70. The inhibitory
effects of HSP70 on IL-6, IL-8 and MCP-1 secretion were
dose dependent, with prominent effects occurring at 1 to 10
μg/ml HSP70. However, treatment with the control protein
ovalbumin [31] did not inhibit TNF-α induced IL-6, IL-8 and
MCP-1 secretion (Figure 2). In addition, similar results were
found when we conducted the same experiment without
washing the FLSs between HSP70 and TNF-α stimulation
(Additional file 1).Arthritis Research & Therapy    Vol 10 No 2    Luo et al.
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Recent studies have shown that contamination of HSP70 with
lipopolysaccharide might be responsible for its stimulatory
activation on macrophages and dendritic cells [32,33]. To test
whether a contamination of our HSP70 preparation with
lipopolysaccharide might have been responsible for the
observed effects of HSP70 on cytokine secretion by FLSs, we
applied a kinetic-turbidimetric method. We first observed that
the recombinant human HSP70 used in this study contained
under 0.01 EU/μg protein (1 pg/μg) bacterial endotoxin. Sec-
ond, the following studies were conducted to exclude the pos-
sibility that such minute amounts of lipopolysaccharide might
affect cytokine secretion by FLSs by using the lipopolysaccha-
ride inhibitor polymyxin B and by boiling the HSP70. Figure 3
shows that the effects of human HSP70 on IL-6, IL-8 and
MCP-1 secretion were completely inhibited by boiling (which
denatures proteins but not lipopolysaccharide) but not by pol-
ymyxin B, whereas the effects of lipopolysaccharide (100 ng/
ml) on IL-6, IL-8 and MCP-1 secretion were inhibited by poly-
myxin B but not by boiling. In addition, in contrast to the inhib-
itory effects of HSP70 on FLSs, lipopolysaccharide exhibited
slightly stimulatory effects on IL-6, IL-8 and MCP-1 secretion
by FLSs (Figure 3). Consequently, we conclude that the
Figure 1
HSP70 alone has no effect on IL-6, IL-8 and MCP-1 secretion in RA  FLSs HSP70 alone has no effect on IL-6, IL-8 and MCP-1 secretion in RA 
FLSs. Rheumatoid arthritis fibroblast-like synoviocytes were incubated 
with tumour necrosis factor (TNF)-α or heat shock protein (HSP)70 at 
the indicated concentrations for 24 hours. The (a) IL-6, (b) IL-8 and (c) 
monocyte chemoattractant protein (MCP)-1 concentrations in the cul-
ture supernatants were determined using ELISA. Data are presented as 
means ± standard deviation of three independent experiments. *P < 
0.05 versus unstimulated control group.
Figure 2
HSP70 inhibits TNF-α induced IL-6, IL-8 and MCP-1 secretion in RA  FLSs HSP70 inhibits TNF-α induced IL-6, IL-8 and MCP-1 secretion in RA 
FLSs. Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs) 
were incubated with the indicated concentrations of heat shock protein 
(HSP)70 or control protein OVA (10 μg/ml) for 1 hour, washed and 
then exposed to tumour necrosis factor (TNF)-α (20 ng/ml). The super-
natants were harvested after 24 hours, and (a) IL-6, (b) IL-8 and (c) 
monocyte chemoattractant protein (MCP)-1 concentrations were deter-
mined using ELISA. Data are presented as means ± standard deviation 
of three independent experiments. *P < 0.05 versus the TNF-α stimu-
lated group.Available online http://arthritis-research.com/content/10/2/R41
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effects of HSP70 on proinflammatory mediator secretion in
FLSs were not influenced by possible lipopolysaccharide con-
tamination in the preparation of HSP70.
Human HSP70 suppresses the phosphorylation of 
MAPKs induced by TNF-α in FLSs
TNF-α-induced inflammatory cytokine production by FLSs
involves the activation of three MAPKs, namely p38, ERK1/2
(p44/42) and JNK (p46/54) [34]. To understand fully the
mechanism by which HSP70 inhibits TNF-α induced proin-
flammatory mediator production by human RA FLSs, we first
investigated the possible effects of HSP70 on the phosphor-
ylation of p38, ERK and JNK. After cells were stimulated by
TNF-α, phosphorylation levels of MAPKs were subsequently
measured by Western blotting analysis using three different
kinds of phospho-specific antibodies. The results indicate that
the phosphorylation levels of all three MAPKs increased dra-
matically after 30 minutes of treatment with TNF-α (20 ng/ml),
which is consistent with previous reports [34]. However, the
phosphorylation of all three MAPK was inhibited when FLSs
were pretreated with human HSP70 and then exposed to
TNF-α for 30 minutes (Figure 4). The inhibitory effects
occurred in a dose-independent manner; maximal inhibition
was achieved with 1 to 10 μg/ml HSP70. Moreover, HSP70
inhibition of the phosphorylation of p38 MAPK was more sig-
nificant as compared with its inhibition of JNK and ERK. With-
out TNF-α stimulation, HSP70 alone did not significantly affect
the phosphorylation of the MAPKs in RA FLSs (date not
shown). Thus, the inhibitory effects of human HSP70 on proin-
flammatory mediator secretion induced by TNF-α in FLSs
could be attributed to the suppression of MAPK pathways.
Human HSP70 inhibits nuclear translocation of NF-κB 
induced by TNF-α in FLSs
Because activation and nuclear translocation of NF-κB is an
essential step in the regulation of production of cytokines [35],
we first examined whether HSP70 could inhibit the TNF-α
induced nuclear translocation of NF-κB by immunofluores-
cence. We found that p65 subunit of NF-κB was distributed in
the cytoplasmic compartment in all cells before TNF-α stimu-
lation. Treatment with TNF-α (20 ng/ml) resulted in marked
accumulation of p65 in nuclei after 30 minutes. However,
nuclear translocation of p65 induced by TNF-α was signifi-
cantly inhibited in cells pretreated with HSP70 (Figure 5).
HSP70 alone, even at high concentrations (up to 10 μg/ml),
could not induce NF-κB nuclear translocation at all (date not
shown).
We further confirmed these results using a Western blotting
approach by probing nuclear and cytoplasmic FLS cell
extracts using monoclonal antibodies specific for the p65 sub-
unit of NF-κB. The results showed that nuclear translocation of
p65 from the cytoplasm to the nucleus occurred at 30 minutes
after TNF-α stimulation (date not shown). Treatment of FLSs
with HSP70 for 1 hours alone did not affect the nuclear trans-
location of NF-κB (date not shown). However, pretreatment of
FLSs with human HSP70 for 1 hour, followed by exposure to
TNF-α for 30 minutes, caused a significant inhibition of NF-κB
translocation to the nucleus, and kept the p65 subunit of NF-
κB in the cytoplasmic compartment (Figure 6a).
Human HSP70 inhibits the TNF-α induced degradation of 
IκBα
In order to examine the roles played by IκBα in the NF-κB acti-
vation pathway by masking the nuclear localization sequence,
we investigated the degradation of IkBα by Western blotting
using antibodies against IκBα. To explore the mechanism by
which HSP70 inhibits the nuclear translocation of NF-κB, we
determined whether HSP70 could inhibit the TNF-α induced
Figure 3
Effects of human HSP70 and lipopolysaccharide Effects of human HSP70 and lipopolysaccharide. The effects of human 
heat shock protein (HSP)70 on proinflammatory mediator secretion in 
fibroblast-like synoviocytes (FLSs) are not due to contaminating lipopol-
ysaccharide (LPS). Rheumatoid arthritis (RA) FLSs were incubated 
with untreated, polymyxin B (PMB; 10 μg/ml)-treated, or boiling(100°C, 
30 minutes)-treated human heat shock protein 70 (HSP70;1 μg/ml) or 
lipopolysaccharide (LPS; 100 ng/ml) for 1 hour, washed and then 
exposed to tumour necrosis factor (TNF)-α (20 ng/ml). The superna-
tants were harvested after 24 hours, and (a) IL-6, (b) IL-8 and (c) 
monocyte chemoattractant protein (MCP)-1 concentrations were deter-
mined using ELISA. Data are presented as means ± standard deviation 
of three independent experiments. *P < 0.05 versus TNF-α alone.Arthritis Research & Therapy    Vol 10 No 2    Luo et al.
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degradation of IκBα. TNF-α (20 ng/ml) markedly induced
degradation of IκBα at 20 minutes, and this degradation was
significantly inhibited in cells pretreated with human HSP70
(Figure 6b). It was therefore concluded that HSP70 can inhibit
the degradation of IκBα and subsequent nuclear translocation
of NF-κB induced by TNF-α.
Discussion
It has been demonstrated that the HSP70 family of proteins
can downregulate adjuvant arthritis [24], and it is likely that the
protection resulted from induction of self-HSP70 cross-reac-
tive T cells that are capable of downregulating inflammation
[22]. However, the mechanism underlying the regulatory effect
of HSP70 in RA is complex and incompletely understood. Syn-
ovial FLSs play a vital role in both chronic inflammation and
joint destruction, principally through synthesis of proinflamma-
tory cytokines and chemokines [36], which play essentially
pathogenetic roles in RA. In the present study we investigated
– for the first time – the effects of human HSP70 on secretion
of the proinflammatory cytokine IL-6 and chemokines IL-8 and
MCP-1 by human RA FLSs. Our results clearly demonstrated
that human HSP70 suppressed TNF-α induced IL-6, IL-8 and
MCP-1 production in a dose-dependent manner in human RA
FLSs. Moreover, we observed that HSP70 suppressed the
activation of the proinflammatory mediator associated NF-κB
and MAPKs signalling pathways induced by TNF-α. Based on
these combined observations, we conclude that extracellular
human HSP70 has anti-inflammatory effects on RA, probably
due to inhibitory effects of HSP70 on production of proinflam-
matory cytokines and chemokines in FLSs.
The roles played by HSP70 in the immune response have
been a focus of many recent investigations [24,37]. HSP70
has been reported to have both proinflammatory and anti-
inflammatory effects in autoimmune diseases [16]. Mammalian
and bacterial HSP70 have been described to activate antigen-
presenting cells directly, including macrophages and dendritic
cells [17]. Such immune activation might contribute to
Figure 4
HSP70 suppresses TNF-α induced phosphorylation of MAPKs in human FLSs HSP70 suppresses TNF-α induced phosphorylation of MAPKs in human FLSs. Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs) were 
incubated with heat shock protein (HSP)70 at 0.1 to 10 μg/ml for 1 hour, and the FLSs were washed and exposed to tumour necrosis factor (TNF)-
α (20 ng/ml) for 30 minutes. The cell lysates were immunoblotted with (a) anti-phospho-p38 (p-p38) and anti-total p38 (t-p38), (b) anti-phospho-
ERK (p-ERK) and anti-total ERK (t-ERK), and (c) anti-phospho-JNK (p-JNK) and anti-total JNK (t-JNK). Antibodies (Abs) against t-p38, t-ERK, or t-
JNK served as controls. The levels of p38, extracellular signal-regulated protein kinase (ERK), and c-Jun amino-terminal kinase (JNK) were estimated 
by densitometry. Shown in the left panels are representative Western blots, and in the right panels are presented the means ± standard deviation of 
three independent experiments. *P < 0.05 versus the TNF-α group. MAPK, mitogen-activated protein kinase.Available online http://arthritis-research.com/content/10/2/R41
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Figure 5
HSP70 inhibits TNF-α induced nuclear translocation of NF-κB in FLSs, as detected using immunocytochemistry HSP70 inhibits TNF-α induced nuclear translocation of NF-κB in FLSs, as detected using immunocytochemistry. Rheumatoid arthritis (RA) fibrob-
last-like synoviocytes (FLSs) were incubated with heat shock protein (HSP)70 (1 μg/ml) for 1 hour, and the FLSs were washed and exposed to 
tumour necrosis factor (TNF)-α (20 ng/ml) for 30 minutes. The cells were fixed, permeabilized and incubated with rabbit anti-p65 antibody, followed 
by Cy3-conjugated anti-rabbit immunoglobulin (red). The nuclei of the corresponding cells were demonstrated by Hoechst 33258 staining. Total 
magnification for images was 200×.Arthritis Research & Therapy    Vol 10 No 2    Luo et al.
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breaking of tolerance to autoantigens, leading to the induction
of autoimmune disease [16]. HSP70 can also regulate
autoimmunity indirectly by activating regulatory T cells that
control pathogenic T cells specific for self-antigens other than
HSPs [24]. HSP70 has also been studied and identified as an
immune target in RA. The HSP70 family of proteins has been
implicated in the pathogenesis of experimental and human
arthritis. Immunization with mycobacterial HSP70 has been
found to protect rats from experimentally induced arthritis
through induction of IL-10 producing T cells [22,23,38]. Intra-
venous or subcutaneous administration of the endoplasmic
reticulum chaperone BiP (a mammalian HSP70 family mem-
ber) was also found to prevent induction of and to treat ongo-
ing collagen-induced arthritis [39]. Elevated levels of antibody
to HSP70 have been reported in RA, and the level of HSP70
has been shown to be enhanced in RA synovial fluid and syn-
ovial tissue [20,21,40].
Although studies on the role of extracellular HSP70 in human
RA are incomplete, a picture is emerging in which the expres-
sion of HSP70 or immune reactivity to HSP70 in RA appears
to be associated with downregulation, rather than induction or
propagation of inflammation. It was recently shown that myco-
bacterial HSP70 treatment in vitro induced IL-10 production
in monocytes from blood and synovial tissue from arthritis
patients [41]. Also, BiP stimulation of human peripheral blood
mononuclear cells in vitro was found to trigger the production
of anti-inflammatory cytokines [42]. However, to our knowl-
edge, the effect of extracellular human HSP70 on human RA
FLSs has not previously been studied.
The present study revealed that human HSP70 inhibited the
IL-6, IL-8 and MCP-1 expression in RA FLSs induced by TNF-
α stimulation (Figure 2), although HSP70 alone had no effect
on FLSs (Figure 1). The findings suggest that self-HSP70 may
Figure 6
HSP70 inhibits translocation of NF-κB and degradation of IκBα HSP70 inhibits translocation of NF-κB and degradation of IκBα. Heat shock protein (HSP)70 inhibits tumour necrosis factor (TNF)-α induced 
nuclear translocation of nuclear factor-κB (NF-κB) and degradation of IκBα in fibroblast-like synoviocytes (FLSs) detected by Western blot. (a) 
Human rheumatoid arthritis (RA) FLSs were incubated with HSP70 at 0.1 to 10 μg/ml for 1 hour, and the FLSs were washed and exposed to TNF-
α (20 ng/ml) for 30 minutes. Nuclear or cytoplasmic lysates were immunoblotted with anti-P65, anti-PCNA (proliferating cellular nuclear antigen), or 
anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase). PCNA and GAPDH served as controls for nuclear and cytoplasmic proteins. The levels 
of p65, GAPDH and PCNA were estimated by densitometry. Shown in the left panels are representative Western blots, and shown in the right pan-
els are the means ± standard deviation of three independent experiments. *P < 0.05 versus the TNF-α group. (b) Human RA FLSs were incubated 
with HSP70 at 0.1 to 10 μg/ml for 1 hour. Then, the FLSs were washed and exposed to TNF-α (20 ng/ml) for 20 minutes. Cytoplasmic lysates were 
immunoblotted with IκBα or anti-tubulin. Tubulin served as a control for cytoplasmic protein. The levels of IκBα and tubulin were estimated by densi-
tometry. Shown in the left panel is a representative Western blot, and shown in the right panel are the means ± standard deviation of three independ-
ent experiments. *P < 0.05 versus the TNF-α group.Available online http://arthritis-research.com/content/10/2/R41
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have anti-inflammatory effects on RA, which might partly be
due to downregulation of proinflammatory mediators by FLSs.
However, HSP70 has also been shown to induce proinflam-
matory cytokines such as TNF-α, IL-1 and IL-6 in monocytes
and macrophages [16,43]. The explanation for these differ-
ences may lie in the different types and/or activation status of
cells used for the experiments. Interestingly, similar extracellu-
lar anti-inflammatory functions for other self-HSPs have also
been suggested. Treatment with human HSP60 of T cells in
vitro was found to inhibit the production of proinflammatory
cytokines TNF-α and interferon-γ, and to trigger production of
the anti-inflammatory cytokine IL-10, which is mediated via
Toll-like receptor 2 [44]. Treatment of human monocytes with
human HSP27 exaggerated IL-10 production [45]. Treatment
with human HSP10 in vitro inhibited lipopolysaccharide-
induced activation of NF-κB; reduced secretion of lipopoly-
saccharide-induced TNF-α, IL-6 and RANTES (regulated on
activation, normal T cell activated and secreted); and
enhanced IL-10 production from human peripheral blood
mononuclear cells [46].
These findings suggest that, rather than being proinflamma-
tory, self-HSP reactivity might be a physiological mechanism
for regulating proinflammatory responses and inflammatory
diseases. It should therefore not be surprising if self-HSP70
were found to have an anti-inflammatory effect in RA. It has
been shown that inflammatory stress induces HSP70 release
from viable human FLSs and normal peripheral blood mononu-
clear cells [21]. It is thus conceivable that, in the inflamed RA
joint, inflammatory stress contributes to the expression and
release of HSP70, and the extracellular HSP70 may act as a
natural dimmer of inflammation, which might regulate both T
cell and FLS mediated inflammation.
Thus far there exists no information about the signalling path-
ways that are involved in HSP70-mediated inhibitory effects
on inflammation in FLSs. Signalling pathways that regulate
proinflammatory mediator expression in RA FLSs include
MAPKs and NF-κB. Three MAPK families have been impli-
cated as playing a role in RA, including ERK1/2, JNK and the
p38 MAPK [34]. Interestingly, all three of these MAPK families
are activated in RA synovial tissue and in cultured RA FLSs,
and TNF-α has the potential to signal through all of them [47].
Our study showed that treatment with HSP70 alone had no
effect on activation of the three MAPKs (date not shown).
However, human HSP70 markedly inhibited TNF-α stimulated
p38, ERK and JNK phosphorylation (Figure 4). This inhibition
was more obvious in TNF-α stimulated p38 phosphorylation.
Collectively, these date suggest that HSP70 may suppress
proinflammatory mediator production in RA FLSs via suppres-
sion of MAPK pathways.
Apart from the MAPKs, NF-κB is another key regulator of
proinflammatory mediator expression and plays an important
role in the induction of inflammatory cytokines in primordial
mesenchymal cell lineages, including lymphocytes, macro-
phages and fibroblasts [35,48]. NF-κB is mainly composed of
two subunits – p50 and p65 – and is retained in the cytosol of
nonstimulated cells by a noncovalent interaction with the inhib-
itory molecule IκB. Upon stimulation by proinflammatory
cytokines such as TNF-α and IL-1, IκB is degradated and NF-
κB is released and translocated to the nucleus to regulate
inflammatory gene expression [35,47]. NF-κB is also over-
expressed in RA synovium [48,49], and activated in RA FLSs
in response to TNF-α and IL-1 [26,47,50]. We found that the
degradation of IκB and subsequent nuclear translocation of
the NF-κB subunit p65 induced by TNF-α were strongly inhib-
ited by human HSP70. Accordingly, we conclude that the
attenuation by HSP70 of proinflammatory mediator production
upon exposure to TNF-α was at least partially mediated by the
suppression of NF-κB pathway. The mechanism by which
HSP70 inhibits the TNF-α induced degradation of IκBα
remains unclear. We speculate that HSP70 in medium may
bind its specific surface receptor on the RA FLSs, and activate
intracellular anti-inflammatory signal transduction pathways
such as JAK2-STAT3-SOCS3, which can inhibit the TNF-α
induced degradation of IκB as well as subsequent activation
and nuclear translocation of NF-κB. Recently, Human RA
FLSs were shown to express high levels of the CD91 molecule
[51], which is a known internalizing receptor for HSP70.
Therefore, it is also possible that HSP70 may interact with the
cell surface via the CD91 receptor, leading to receptor medi-
ated endocytosis. Once taken up, HSP70 may function in the
same way as does intracellular HSP70, which exerts its chap-
erone functions and inhibits degradation of IκBα.
Conclusion
In this study we demonstrate a novel role for exogenous
human HSP70 in suppressing proinflammatory mediator pro-
duction by human RA FLSs. The anti-inflammatory role played
by human HSP70 in human RA FLSs may be accounted for by
its ability to downregulate TNF-α induced activation of MAPK
and NF-κB, two vital inflammatory signal pathways in FLSs of
inflammation in RA. The results of this study indicate that
human HSP70, which is upregulated and released in
response to stress and inflammation, can function as a down-
regulator of FLS-induced inflammation in RA.
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